Background: Combination therapy with three classes of drug, antiplatelet, cholesterol and blood pressure lowering treatment markedly reduce the risk of recurrent cardiovascular events in patients with coronary heart disease (CHD). Within each class, generic and branded (patented) drugs are available which have similar efficacy but differ in cost. Aims: (i) To assess the extent to which preventive medical drugs are prescribed in patients with CHD and to examine the reasons for drug omissions and (ii) to assess the relative use of branded and generic drugs and the reasons for drug selection. Methods: The medication charts and hospital notes of consecutive patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) at a large cardiothoracic centre were reviewed over a 3-month period. Interviews with patients, attending cardiologists and general practitioners were undertaken to establish why drugs were and were not prescribed. Results: Among 1008 patients (755 who had PCI and 253 who had CABG) the use of aspirin, statins, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), beta blockers
and calcium channel blockers were, respectively, 97, 98, 81, 76 and 18%. The combination of any 4 classes of drug were used in 65% of patients. Almost all patients who did not receive aspirin or a statin had clinical contraindications and were on alternative drugs. In about 12% of patients without an ACE inhibitor (or ARB) and 7% of patients without a beta blocker, no reason to withhold such treatment was identified. Branded drugs were used in 52% of patients; the most commonly prescribed being atorvastatin in 33%. Clinical reasons for using branded rather than generic drugs were identified in 13% of cases. Conclusion: Our results show a high rate of use of secondary preventive cardiac medications in patients undergoing coronary revascularization procedures, but the use of ACE inhibitors or beta blockers is still overlooked in about 1 in 10 patients. Branded drugs are prescribed in about half of all patients undergoing PCI and CABG, but in almost 90% of cases, a generic equivalent could have been used to achieve similar risk reduction. If our results reflect wider practice, an estimated £11 million a year would be saved by the National Health Service by switching to generic alternative drugs.
Introduction
It is widely recognized that combination therapy with antiplatelet, lipid lowering and blood pressure lowering drugs substantially reduces the risk of cardiovascular events in patients with coronary heart disease (CHD). [1] [2] [3] The use of aspirin, a statin and combination blood pressure lowering therapy [specifically, a beta blocker and an angiotensinconverting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)] are recommended by The National Institute for Health and Clinical Excellence (NICE) 4 in patients who have had a myocardial infarction and can be justified in all patients with CHD in view of their high risk of recurrent events and death and the marked benefits from combination therapy. 5, 6 It is estimated that about 50% of patients with CHD in the UK do not receive adequate preventive therapy 7 and that patients treated by surgeons [undergoing coronary artery bypass grafting (CABG)] compared to cardiologists [undergoing percutaneous coronary intervention (PCI)] are particularly undertreated. [8] [9] [10] [11] Surveys on the use of drug therapy have tended to rely on examination of general practice or hospital prescribing registers and do not provide information on the reasons for drug omissions. [8] [9] [10] [11] There is consequently a lack of information on the extent to which shortfalls in treatment can be reasonably corrected.
The use of aspirin, statins and blood pressure lowering drugs in patients with CHD has been judged cost-effective, 4 but the selection of branded or generic drugs within a class may significantly affect drug expenditure. For example, the choice of statin can differ by 14-fold in cost (one pack of simvastatin 40 mg costs £1.31, whereas one pack of atorvastatin 10 mg costs £18.03) without an expectation of improving clinical outcome. 12 A recent metaanalysis of 47 trials comparing branded and generic drugs across nine cardiovascular drug classes concluded there was no evidence to support superiority of branded over generic medications despite the negative view of generic equivalents often held in editorials. 13 Cardiovascular prescriptions contribute to almost a quarter of the total National Health Service (NHS) prescribing bill.
14 Quantifying the proportion of branded and generic secondary preventive cardiac drugs used in clinical practice and the reasons for branded selection are therefore important steps in determining whether costs can be rationally reduced.
This prompted us to undertake a study to examine the use of medical treatments by patients with CHD undergoing CABG or PCI to see whether they were receiving recommended preventive medical treatment and to explore the reasons, on a case-by-case basis, for prescribing omissions. For each class of drug, we sought to quantify the extent to which branded and generic drugs were used, the rationale for such choices and the cost implications that follow from them.
Methods
Information on the drugs prescribed to patients on the cardiac wards at two London hospitals within Barts and the London NHS Trust was prospectively collected over a 15-week period from November 2006 to March 2007. For each patient, the medication charts and hospital records were examined to obtain a record of age, gender, allergies and drug intolerance, comorbidities (such as diabetes and asthma), smoking habits and the revascularization procedure undertaken (CABG or PCI). The medication charts were examined for details of drugs prescribed at the end of their hospital stay just prior to discharge from hospital. A random sample of 100 records was re-examined by a second investigator to verify the accuracy of the data collected. The number and proportion of patients taking each class of drug and combinations of classes was determined separately for patients undergoing CABG and PCI. Differences between groups were considered significant at P < 0.05, calculated by Pearson's; chi-squared with STATA software (Statacorp, College Station, Texas, USA).
When either aspirin, a statin, an ACE inhibitor/ ARB or a beta blocker were found to be absent from a patient's chart, we explored why, firstly by checking the hospital records, then by asking the patient for any previous intolerance to the specified class of drug, then by asking the attending hospital physician whether there was a contraindication to treatment, and in cases where uncertainty remained, by contacting the patient's General Practitioner for additional information. In all cases where the use of a recommended class of drug had been overlooked and the responsible physician knew of no clinical contraindication or objection to the drug being used, we recorded 'no clinical reason' for its omission. The proportions of branded and generic drugs prescribed were also recorded and the reasons for the selection examined in the same way.
To assess the extent to which drugs initiated in hospital were continued in primary care, a sample of 100 randomly selected patients from the original cohort were contacted by phone 6 months after discharge from hospital and asked which medications they were taking and the reasons for any changes to treatment.
Results
Data were collected from 1008 patients, 755 who had undergone PCI and 253 who had received CABG. A total of 3739 cardiac drugs were prescribed, of which 2852 were in the PCI group (mean 3.80 per person) and 887 in the CABG group (mean 3.50 per person). The baseline characteristics of the patients and their medication use, both for the individual drugs and drug combinations, at discharge from hospital are shown in Table 1 . There were no differences in the use of statins, ACE inhibitors or ARBs between patients treated by PCI and CABG. Aspirin, beta blockers and calcium channel blockers were used more among patients treated by PCI than among patients treated by CABG (99 vs 92%, 78 vs 72% and 20 vs 10%, respectively; P < 0.001 for all comparisons). The use of combination therapy was also greater among patients treated by PCI than CABG; combinations of aspirin, a statin and at least two blood pressure lowering drugs were used in 70% and 59% of such patients, respectively (P = 0.002). Table 2 shows the number of patients who did not receive either aspirin, a statin, an ACE inhibitor/ARB or a beta blocker together with the reasons for such drug omissions. The most common reason for not taking a specified class of drug was previous intolerance to the drug (notably gastrointestinal bleed for aspirin, myalgia or diarrhoea for statins, asthma or hypotension for beta blockers, and hypotension or renal impairment for ACE inhibitors or ARBs). In 7.4% of patients who did not receive a beta blocker and 12.4% who did not receive an ACE inhibitor/ ARB, no clinical reason for withholding treatment was given (the use of the drug had been overlooked without a medical contraindication to its use) and no suitable alternative drug used. Table 3 shows, across all classes of drug, the number and proportion of patients receiving generic and branded drugs. There were no statistically significant differences in the use of branded drugs between patients treated by PCI and CABG. Overall, 52% of patients were taking at least one branded drug at the time of discharge from hospital. Figure 1 shows the proportion of branded and generic drugs according to drug class, and Figure 2i -iv gives the specific drugs within each class that account for these proportions. Branded drugs represented about one-third of all statin prescriptions (atorvastatin 33%, rosuvastatin 3%), onequarter of all ACE/ARB prescriptions (perindopril 13% and any ARB 12%) and almost one-fifth of all beta blocker prescriptions (<5 mg bisoprolol 17%).
Clinical reasons for the use of branded over generic drugs were found in 45 (8%) of the 363 patients discharged on branded statins; 42 patients for a high cholesterol, two because of intolerance to simvastatin, and one because morning dosing was required (favouring atorvastatin). Clinical reasons to justify the use of an ARB were present in 8% of patients who were discharged on ARBs (7 out of 87); all because they had previously experienced a cough on an ACE inhibitor. Perindopril was used in 104 patients without a specific clinical indication. Lowdose bisoprolol (<5 mg) was prescribed in 126 patients, 35 (28%) because of left ventricular dysfunction. In the sample of 100 patients contacted 6 months after discharge from hospital, most were taking the same combination prescribed when they left hospital. There was, however, a 6% increase in the proportion of patients receiving at least one branded drug.
Discussion
The use of combination therapy to reduce multiple cardiovascular risk factors with aspirin, a statin and two or more blood pressure lowering drugs is advocated for all patients with CHD and has the potential to reduce risk by about 80%. 6 Our results indicate that the uptake of combination treatment is high among patients undergoing PCI and CABG, a group with confirmed CHD in whom such treatment is recommended, [1] [2] [3] [4] [5] [6] with about two-thirds of patients receiving at least four or more different classes of secondary preventive drug. This indicates an increase in the use of these treatments compared with previous reports and shows a narrowing of the reported gap [8] [9] [10] [11] in prescribing between patients treated by CABG and PCI.
Previous surveys have examined the extent to which medically indicated drugs are used in practice, [5] [6] [7] [8] [9] [10] [11] but not the clinical reasons for drug omissions. In our study, medical justifications for not prescribing recommended drugs were present in almost all cases where aspirin and statins were withheld (gastric intolerance and myalgia being the principal contraindications reported) and reasonable alternative drugs were given. However, in the case of beta blockers and ACE/ARBs, medical justifications were lacking. Hypotension was given as a reason to withhold such treatment for both classes of drug, although the mean blood pressure was 113/63 in those not receiving beta blockers and 120/60 in those not receiving an ACE inhibitor or ARB. Cohort studies show no blood pressure threshold below which further reductions in blood pressure cease to reduce the risk of a CHD, 15 so withholding such treatment on the basis of a 'low' blood pressure is unnecessary and limits the preventive potential of drug therapy. A significant minority of patients had at least one class of blood pressure lowering drug withheld without justification: 7% for beta blockers and 12% for ACE or ARB. These results indicate the potential for improving the medical treatment of patients with CHD. This is the first study to quantify and characterize the use of branded and generic drugs on a class-specific basis. Overall, about half of all patients received a branded drug. Atorvastatin accounted for about one-third of all statin prescriptions (325 patients). About half of these (55%) were for atorvastatin 10 or 20mg which is similar in efficacy and side-effects to simvastatin 40 mg, but more than 10 times the cost. 16 In the remaining patients taking a higher dose of atorvastatin (40 or 80 mg), only about one-quarter (42 patients) had a specific indication for the higher doses used (high-risk patients with particularly high cholesterol). 17 So, whilst switching from atorvastatin to simvastatin may not be appropriate in all patients, if a specific indication for its use exists, our results indicate that such a policy would have been reasonable in most. It is relevant to note, that the National Audit Office published recommendations during the course of our study supporting proposals to switch patients who are taking atorvastatin 10 or 20 mg to simvastatin 40 mg, because of the substantial cost savings that would be achieved. 14, 18 The National Prescribing Centre reported in June 2008 that ARBs represented 28% of all prescriptions to patients receiving either an ACE inhibitor or an ARB in primary care in England in the previous year and accounted for 62% of the cost. 19 Our results suggest a lower rate of use of ARBs (12%) in secondary care and show that clinical justification for use of an ARB over an ACE inhibitor was present in only 7% of such patients-all previously having developed a cough on an ACE inhibitor. Whilst ARBs are better tolerated than ACE inhibitors for this reason, 20 there is no evidence of increased blood pressure reduction or a mortality benefit of one over the other. 21, 22 ACE inhibitors are therefore the preferred option until generic ARBs become available at lower cost. Until then, and possibly for some time afterwards, as price reductions are unlikely to be immediate, there are considerable opportunities for reducing costs by prescribing ACE inhibitors as first line drugs rather than ARBs in patients with CHD.
Bisoprolol, at low doses (1.25, 2.5 and 3.75 mg) is branded and licensed for use in patients with moderate and severe left ventricular dysfunction; 23 higher doses are generic. Branded bisoprolol was used in 8% of patients, most (about two-thirds) of whom had normal or mildly impaired left ventricular dysfunction and no clinical evidence of heart failure. In these patients atenolol would have been a reasonable and less expensive alternative.
In the sample of 100 patients contacted by phone six months following discharge from hospital, there were few changes to the drugs prescribed at discharge from hospital. When changes were made, this increased (by 6%) rather than decreased the use of branded drugs.
Our study has certain limitations. The results apply to selected patients undergoing revascularization at two large cardiac hospitals and may not be representative of other patients with CHD in other clinical settings. Data collection from hospital records and medication charts is also prone to transcription errors, although an independent check by a second investigator on a sample of 100 records showed this to be reasonably accurate (two corrections were required). We may have underestimated the proportion of patients with valid clinical reasons for either not receiving specified drugs or receiving branded over generic ones, if our systematic enquiry missed valid explanations. We went to considerable lengths to identify such reasons, by examining hospital records and interviewing patients, their hospital physicians and general practitioners. However, even if we had underestimated such reporting by a factor of two, this would still mean that 1 in 20 patients were undertreated (not receiving an ACE inhibitor or a beta blocker) and that 1 in 4 branded drugs were being prescribed instead of generic alternatives. Table 4 shows the observed costs of prescriptions per patient (based on Monthly Index of Medical Specialities (MIMS) pricing, October 2008) in our population for a 28-day supply of each specified class of drug. The best-and worse-case cost scenarios are shown for branded and generic selections, respectively. The cost per patient per month was £12.79, compared with a best-case cost of £3.54 (assuming no use of branded therapy), 12 a potential saving of £9.25 per patient per month. The projected saving to our hospital over a year would be about £41 600 and to the Primary Care Trust (PCT) about £457 900, based upon the annual activity (4500 per year) of patients undergoing PCI or CABG, and taking into account that the hospital provides drugs for one month on discharge from hospital and the PCT pays for the remaining 11 months of the year. If our results reflect general NHS prescribing practice, this would represent a potential saving of about £11 100 000 to the NHS per year [based on the approximate number (100 000) of patients undergoing PCI and CABG in the UK each year]. 24 Our results show a high rate of use of combination therapy with antiplatelet, cholesterol and blood pressure lowering drugs among patients with CHD undergoing PCI and CABG. Nine out of 10 patients were prescribed at least a 3-drug combination (one drug from each class) and about two-thirds, a 4-drug combination (aspirin, a statin and at least two blood pressure lowering drugs). Most patients not receiving a particular drug had valid medical reasons for its omission, except in the case of blood pressure lowering treatment where 1 in 10 patients had medication withheld without justification. This high level of prescribing has led to a new clinical priority; that of generic vs branded drug selection within a specified class. Our survey shows that whilst there may be clinical situations where branded drugs are better and so justify the cost, in most cases (90%) when branded drugs are used, a generic equivalent would have comparable efficacy and safety, at a much reduced cost to the NHS.
